Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Chronische hepatitis B: wie kan stoppen met nucleos(t)ideanalogen?
jun 2022 | Hepatitis, Hepatologie, Virale infecties